|1.||Stohl, William: 16 articles (07/2012 - 08/2002)|
|2.||Gottenberg, Jacques-Eric: 9 articles (01/2015 - 01/2006)|
|3.||Mackay, Fabienne: 9 articles (01/2013 - 07/2002)|
|4.||Hilbert, David M: 9 articles (01/2008 - 02/2002)|
|5.||Mariette, Xavier: 8 articles (04/2013 - 04/2004)|
|6.||Zhang, Shuangquan: 7 articles (12/2015 - 10/2005)|
|7.||Migone, Thi-Sau: 7 articles (07/2012 - 04/2003)|
|8.||Sibilia, Jean: 6 articles (01/2015 - 01/2006)|
|9.||Zhong, Z John: 6 articles (05/2014 - 02/2011)|
|10.||De Vita, Salvatore: 6 articles (02/2013 - 04/2004)|
|1.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
08/15/2006 - "Constitutive overexpression of B cell-activating factor belonging to the TNF family (BAFF) promotes development of systemic lupus erythematosus (SLE), and treatment of SLE mice with BAFF antagonists ameliorates disease. "
09/01/2015 - "A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study."
09/01/2015 - "To evaluate the efficacy and safety of subcutaneous blisibimod, an inhibitor of B cell activating factor, in patients with systemic lupus erythematosus (SLE) in a dose-ranging Phase 2b clinical trial. "
09/01/2013 - "The B lymphocyte stimulator (BLyS)-A PRoliferation-Inducing Ligand (APRIL) signaling pathway has an important role in the selection, maturation and survival of B cells and plays a significant role in the pathogenesis of systemic lupus erythematosus (SLE). "
07/01/2013 - "Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort."
01/01/2014 - "The objective of this study was to evaluate the long-term safety and efficacy of tabalumab, a monoclonal antibody that neutralizes membrane-bound and soluble B-cell-activating factor, in rheumatoid arthritis (RA) patients. "
01/01/2014 - "A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis."
08/01/2015 - "Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O)."
12/01/2015 - "B-lymphocyte stimulator (BLyS) plays a critical role in the pathogenesis and progression of rheumatoid arthritis (RA). "
08/01/2015 - "The efficacy and safety of 2 different dosing regimens of tabalumab, a monoclonal antibody that neutralizes membrane-bound and soluble B-cell-activating factor (BAFF), were evaluated in patients with rheumatoid arthritis. "
10/01/2015 - "Elevated expression of the TNF family member B-lymphocyte stimulator (BLyS) in multiple myeloma (MM) has been described recently. "
01/01/2015 - "B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?"
12/01/2013 - "To explore the regulating effect of miR-202 on B cell-activating factor, and check whether the regulation influences the growth of multiple myeloma cells. "
12/01/2013 - "[Effect of miR-202 on the growth of multiple myeloma cells via regulating B cell-activating factor and the underlying mechanism]."
09/01/2012 - "B cell-activating factor: its clinical significance in multiple myeloma patients."
|4.||B-Cell Lymphoma (Lymphoma, B Cell)
01/01/2014 - "A novel VHH antibody targeting the B cell-activating factor for B-cell lymphoma."
02/15/2009 - "DC-produced survival factors such as B cell-activating factor of the TNF family and a proliferation-inducing ligand have been shown to be essential for B cell maturation, but have also been implicated in class-switch recombination and B cell lymphoma survival. "
03/01/2003 - "This unique binding profile suggests that a radiolabeled form of BLyS protein may be a useful treatment for B cell neoplasias such as B cell lymphoma and multiple myeloma. "
04/01/2011 - "[Expression and significance of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in multiple myeloma]."
04/01/2011 - "This study was aimed to explore the expression of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in bone marrow mononuclear cells (BMMNC) of multiple myeloma (MM) and the significance of BAFF and BCL-2 for occurrence, development and prognosis of MM. The bone marrow of 40 cases of MM and 10 healthy persons was collected, the mononuclear cells (MNC) were isolated, the expression of BAFF and BCL-2 mRNA in BMMNC was detected by real-time PCR; the plasma was simultaneously collected and the β2-MG level was determined; the clinical staging of MM patients was performed according to Durie-Salmon (D-S) staging criterion. "
|5.||Graft vs Host Disease (Graft-Versus-Host Disease)
05/01/2014 - "Excessive levels of B cell activating factor (BAFF) are found in patients with active chronic graft-versus-host disease (cGVHD). "
10/15/2007 - "High levels of B-cell activating factor in patients with active chronic graft-versus-host disease."
05/01/2010 - "High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation."
05/01/2014 - "Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease."
12/08/2011 - "Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis."
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||B-Cell Activation Factor Receptor
|6.||Messenger RNA (mRNA)
|7.||Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)
|8.||B-Cell Maturation Antigen
|10.||Inosine Triphosphate (ITP)
|1.||Stem Cell Transplantation
|3.||Transplantation (Transplant Recipients)
|4.||Hematopoietic Stem Cell Transplantation